Yesterday, Human Genome Sciences (HGSI) more than tripled in value. Voume has increased by twice that. Thus far, today it is up another 10%. Don't chase performance. I know about the lupus trial. I know it's been upgraded. So does everybody. You missed your opportunity to buy this was days ago, before it took out its 52-week high. Don't rush into a money-losing biotech just because of momentum. Unless of course, you have a strong stomach.
No comments:
Post a Comment